Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A2 | P23975 | 20/20 | 0.58 |
| ▸ | SLC6A4 | P31645 | 20/20 | 0.58 |
| ▸ | SLC6A3 | Q01959 | 16/20 | 0.58 |
| ▸ | KCNH2 | Q12809 | 9/20 | 0.56 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.53 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17043097 | 0.87 | SLC6A2 (0.60) | SLC6A2SLC6A4SLC6A3KCNH2OPRK1 | |
| SCHEMBL30948781 | 0.84 | SLC6A2 (0.58) | SLC6A2SLC6A4SLC6A3KCNH2OPRK1 | |
| SCHEMBL34474393 | 0.78 | SLC6A2 (0.52) | SLC6A2SLC6A4SLC6A3KCNH2OPRK1 | |
| SCHEMBL966031 | 0.77 | SLC6A2 (0.51) | SLC6A2SLC6A4SLC6A3KCNH2OPRK1 | |
| SCHEMBL27707181 | 0.76 | SLC6A2 (0.50) | SLC6A2SLC6A4SLC6A3KCNH2OPRK1 | |
| SCHEMBL21606459 | 0.75 | PIK3CD (0.65) | SLC6A2SLC6A4SLC6A3KCNH2OPRK1 | |
| SCHEMBL18872575 | 0.74 | SLC6A4 (0.46) | SLC6A2SLC6A4SLC6A3KCNH2CYP2D6 | |
| SCHEMBL16408232 | 0.74 | SLC6A4 (0.46) | SLC6A2SLC6A4SLC6A3KCNH2CYP2D6 | |
| SCHEMBL16408333 | 0.74 | SLC6A4 (0.46) | SLC6A2SLC6A4SLC6A3KCNH2CYP2D6 | |
| SCHEMBL4634809 | 0.74 | SLC6A2 (0.78) | SLC6A2SLC6A4SLC6A3KCNH2OPRK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210221796-A1 | ANTIBACTERIAL COMPOUNDS | BLACKSMITH MEDICINES, INC. | 2021-07-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210221796-A1 | ANTIBACTERIAL COMPOUNDS | SPOUT1, MRPL21, NRDC | SLC6A2 3942/4885SLC6A4 4383/4885SLC6A3 3390/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.